Navigation Links
Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients
Date:11/1/2008

N A (58%). Depression was most common at 29%. Suicidal behavior including ideation, suicidal attempts, and completed suicides occurred in 1% of patients during or shortly after completing treatment with PEGINTRON.

The following serious or clinically significant adverse events have been reported at a frequency less than 1% with PEGINTRON or interferon alpha: Severe decreases in neutrophil or platelet counts, hypothyroidism, hyperglycemia, hypotension, arrhythmia, ulcerative and hemorrhagic colitis, development or exacerbation of autoimmune disorders including thyroiditis, RA, systemic lupus erythematosus, psoriasis, pulmonary disorders (dyspnea, pulmonary infiltrates, pneumonitis and pneumonia, some resulting in patient deaths), urticaria, angioedema, bronchoconstriction, anaphylaxis, retinal hemorrhages, and cotton wool spots.

In the PEGINTRON/REBETOL combination trial, the incidence of serious adverse events was 17% in the PEGINTRON/REBETOL groups compared to 14% in the INTRON A/ REBETOL group. The incidence of severe adverse events in the PEGINTRON/REBETOL combination therapy trial was 23% in the INTRON A/REBETOL group and 31-34% in the PEGINTRON/REBETOL groups. Dose reductions due to adverse reactions occurred in 42% of patients receiving PEGINTRON (1.5 mcg/kg)/REBETOL and in 34% of those receiving INTRON A/REBETOL.

In a study with weight-based ribavirin, there was a higher rate of anemia among patients in the weight-based dosing group (29%) compared to the flat-dosing group (19%). The majority of these cases were mild and responded to dose reductions. Serious adverse events were similar between the two groups (12%), and discontinuations for adverse events (15% in weight-based dosing and 14% in flat dosing) were also similar. Dose modifications due to adverse events occurred more frequently in the weight-based dosing group (29%) compared to the flat-dosing (23%) group.

Additional Safety Information

Relapse of drug addiction/over
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response
2. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
3. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
5. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
6. Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
9. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
10. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2
... PRINCETON, N.J., Jan. 4, 2011 Pharmasset, Inc. (Nasdaq: ... 29th Annual J.P. Morgan Healthcare Conference to be held January ... CA. Schaefer Price, President and Chief Executive Officer, will provide ... at 9:00 AM (PT). To access a simultaneous ...
... Jan. 4, 2011 Boston Scientific Corporation (NYSE: ... M.D., Chief Medical Officer, Cardiac Rhythm Management, on an article ... the American Medical Association .  The article reported on a ... received an implantable cardioverter defibrillator (ICD) did not meet evidence-based ...
Cached Medicine Technology:Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference 2Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference 3Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article 2
(Date:4/23/2014)... was safe and effective in treating patients with ... , according to a new pilot study published ... online. Known as fecal microbiota transplantation, the treatment ... or a nasogastric tube. The findings suggest approaches ... available to patients. , A growing concern, ...
(Date:4/23/2014)... have developed a new way to detect when ... wheel. , Their recently patented technology is based ... drowsy driversand offers an affordable and more reliable ... systems. , Van Dongen"Video-based systems that use cameras ... of its lane are cumbersome and expensive," said ...
(Date:4/23/2014)... Va., April 23, 2014 The American Society for ... "The Role of Postoperative Radiation Therapy for Endometrial ... use of adjuvant radiation therapy in the treatment ... published in the May-June 2014 issue of ... practice journal of ASTRO. The full-length guideline is ...
(Date:4/23/2014)... pathway that helps prevent new cells from receiving too ... been directly linked to cancer and other diseases. , ... the end of cell division, the enzyme Cdc14 activates ... are fully repaired before the parent cell distributes copies ... safeguard against some of the most devastating genome errors, ...
(Date:4/23/2014)... Rochelle, NY, April 23, 2014Men whose testosterone falls below ... and to be overweight and have heart disease and ... to identify testosterone-deficient men for further testing and possible ... of Men,s Health , a peer-reviewed publication from Mary ... on the Journal of Men,s Health website ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:WSU innovation improves drowsy driver detection 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... - Company to Webcast Presentation at 9:30 a.m. ET on ... Corporation,(Nasdaq: SMTS ) is scheduled to participate in the ... 22, 2008 at the New York Hilton., Bruce J. ... presentation that will be webcast live on Wednesday,May 21, 2008 ...
... have used cough medicine for children younger than two ... effective for children in this age group, an Australia-first ... and Royal Childrens Hospital study, surveyed 325 parents at ... care centres about their use of over-the-counter medication for ...
... The International Association for Dental Research (IADR) ... winners of the annual IADR/GSK Innovation in Oral ... innovative oral care technologies that may maintain and ... Sharing the $225,000 unrestricted research grant, which is ...
... 2008 Canadian researchers have shown that an electric ... neurologic and neuropsychological symptoms in humans. , Following ... and behavioral aftereffects, such as memory loss and symptoms ... grant from Hydro-Qubec and conducted by clinicians from the ...
... 15, 2008 Physicians and dentists should collaborate to ... or may develop osteoporosis, say researchers in the cover ... the American Dental Association. , The authors of the ... the medical and dental literature to examine osteoporosis effect ...
... with ICG-Guided Therapy On Over 76,000+ ... ... 15 CardioDynamics (Nasdaq:,CDICD), the innovator and leader of Impedance ... today,announced the presentation of a significant independent ICG clinical study,at ...
Cached Medicine News:Health News:Somanetics Corporation to Present at Citigroup 2008 Healthcare Conference 2Health News:Study finds parents use cough medicines on under-2s despite the warnings 2Health News:IADR and GlaxoSmithKline Consumer Healthcare announce winners 2Health News:IADR and GlaxoSmithKline Consumer Healthcare announce winners 3Health News:Electric shocks can cause neurologic and neuropsychological symptoms 2Health News:CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting 2Health News:CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting 3
Automatic tangent screen with plane type central field tester. Static, quantitative perimetry....
... represents the latest breakthrough in visual ... the Humphrey Matrix will help you ... and assess treatment alternatives. Enhanced patient ... complete long-term glaucoma care for your ...
Preference Toric quarterly planned replacement lenses are durable, easy to handle and virtually maintenance free. Meeting the needs of those suffering from astigmatism, these soft contact lenses are ...
... and disposable lens convenience for those with ... want crisp, clear vision with the convenience ... Vertex Toric lenses are manufactured using our ... a perfect edge on every lens. This ...
Medicine Products: